Results 181 to 190 of about 78,014 (306)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz   +13 more
wiley   +1 more source

The role of IgM anti‐acetylated protein antibodies and B cells in the origin of anti‐modified protein autoimmunity in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Rheumatoid arthritis (RA) is characterized by anti‐modified protein antibodies (AMPAs), including anti‐citrullinated (ACPA), anti‐carbamylated (anti‐CarP), and anti‐acetylated (AAPA) protein antibodies. In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role in early immune responses.
Aegli Athanasiadou   +10 more
wiley   +1 more source

Utility of Antinephrin Autoantibody-to-IgG Ratio in Autoimmune Podocytopathies. [PDF]

open access: yesKidney Int Rep
Miura K   +9 more
europepmc   +1 more source

Increased plasma microbial tDR‐1 in at‐risk individuals is associated with decreased conversion to clinical rheumatoid arthritis and reduces an in vitro macrophage type 1 interferon response

open access: yesArthritis &Rheumatology, Accepted Article.
Background Microbial small RNAs (sRNAs) can regulate human genes. Higher plasma concentrations of microbial tRNA‐derived RNA‐1 (tDR‐1) were previously associated with lower rheumatoid arthritis (RA) disease activity. This study examined whether tDR‐1 concentrations differ in anti‐cyclic citrullinated peptide‐3 positive (CCP3+) at‐risk individuals (ARI)
Anastasiia Phothisane   +11 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

Natural history of a pediatric cohort with islet autoantibody positivity: a single-center retrospective cohort study. [PDF]

open access: yesJ Endocr Soc
Casalini E   +11 more
europepmc   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

open access: yesBMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy